Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Total Iron Binding Capacity

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    30 result(s) found for: Total Iron Binding Capacity. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2010-023589-39 Sponsor Protocol Number: ST10-01-302 Start Date*: 2012-04-10
    Sponsor Name:Iron Therapeutics (Switzerland) AG
    Full Title: A prospective, multicentre, randomised, double-blind, placebo controlled study with oral ST10-021 for the treatment of iron deficiency anaemia in subjects with quiescent Crohn's Disease where oral ...
    Medical condition: Iron deficiency anaemia in quiescent Crohn's Disease
    Disease: Version SOC Term Classification Code Term Level
    17.0 10005329 - Blood and lymphatic system disorders 10002062 Anaemia iron deficiency LLT
    17.0 10005329 - Blood and lymphatic system disorders 10022972 Iron deficiency anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) GB (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2010-023588-16 Sponsor Protocol Number: ST10-01-301 Start Date*: 2012-04-10
    Sponsor Name:Iron Therapeutics (Switzerland) AG
    Full Title: A prospective, multicentre, randomised, double-blind, placebo controlled study with oral ST10-021 for the treatment of iron deficiency anaemia in subjects with quiescent ulcerative colitis where or...
    Medical condition: Iron deficiency anaemia in quiescent ulcerative colitis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10005329 - Blood and lymphatic system disorders 10002062 Anaemia iron deficiency LLT
    17.0 10005329 - Blood and lymphatic system disorders 10022972 Iron deficiency anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) AT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2021-000348-22 Sponsor Protocol Number: KER047-IR-201 Start Date*: 2021-08-10
    Sponsor Name:Keros Therapeutics, Inc.
    Full Title: A Phase 2, Open-label, Dose Escalation and Dose Expansion Study of KER-047 for the Treatment of IRIDA
    Medical condition: Iron-Refractory Iron-Deficiency Anemia (IRIDA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002192-10 Sponsor Protocol Number: ST10-01-103 Start Date*: 2017-02-16
    Sponsor Name:Shield TX (UK) Limited
    Full Title: A phase 1, open label, randomised, repeat dose, parallel group study to evaluate the pharmacokinetics, safety and tolerability of ferric maltol at the three dosage levels in paediatric subjects age...
    Medical condition: Iron deficiency (with or without anaemia)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10022972 Iron deficiency anaemia PT
    20.0 100000012842 10002062 Anaemia iron deficiency LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-001593-25 Sponsor Protocol Number: P-Monofer-IBD-01-Extension Start Date*: 2011-06-08
    Sponsor Name:Pharmacosmos A/S
    Full Title: An Open-label, Multi-Centre, Non-Randomised Extension Study to Assess the Ability to Maintain a Stable Haemoglobin and to Assess Safety of Iron Isomaltoside 1000 (Monofer®) in Subjects with Inflamm...
    Medical condition: Inflammatory bowel disease subjects with iron deficiency anaemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10017947 - Gastrointestinal disorders 10021972 Inflammatory bowel disease PT
    16.1 10005329 - Blood and lymphatic system disorders 10022972 Iron deficiency anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2009-016727-53 Sponsor Protocol Number: P-Monofer-CIA-01 Start Date*: 2010-04-12
    Sponsor Name:Pharmacosmos A/S
    Full Title: A phase III, randomized, open-label study of intravenous iron isomaltoside 1000 (Monofer®) as mono therapy (without erythropoeisis stimulating agents) in comparison with oral iron sulfate in subjec...
    Medical condition: non-myeloid malignancies associated with chemotherapy induced anaemia (CIA).
    Disease: Version SOC Term Classification Code Term Level
    12.1 10064014 Cancer anemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) GB (Completed) SE (Completed) DE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-000307-93 Sponsor Protocol Number: CICL670F2105 Start Date*: 2016-03-09
    Sponsor Name:Novartis Pharmaceuticals Corporation
    Full Title: A randomized, open label, single center, phase I, two way, cross-over study to evaluate the pharmacokinetic comparability of deferasirox new granule formulation with the reference dispersible formu...
    Medical condition: Healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2009-017409-13 Sponsor Protocol Number: MD2009.04 Start Date*: 2010-06-30
    Sponsor Name:Sanquin Plasma Products
    Full Title: Dose escalating study to evaluate pharmacokinetics, efficacy and safety of apotransferrin in atransferrinemia patients. Estudio de escalada de dosis para evaluar la farmacocinÊtica, la eficacia y l...
    Medical condition: Atransferrinemia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10044357 Transferrin increased LLT
    12.1 10005620 Blood iron increased LLT
    12.1 10002272 Anemia LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) DE (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-002661-35 Sponsor Protocol Number: FERRICCABG01 Start Date*: 2020-04-23
    Sponsor Name:King's College London [...]
    1. King's College London
    2. King's College Hospital NHS Foundation Trust
    Full Title: Effect of Iron Isomaltoside on Perioperative Myocardial Injury in Patients Undergoing Coronary Artery Bypass Graft ± Valve Surgery: The Ferric Iron in Coronary Artery Bypass Grafting (FERRIC-CABG) ...
    Medical condition: Coronary or heart valve disease needing cardiac surgery
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10068617 Coronary heart disease LLT
    20.0 100000004849 10019316 Heart valve disorders LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2016-000248-32 Sponsor Protocol Number: CICL670F2102 Start Date*: 2016-03-15
    Sponsor Name:Novartis Pharmaceuticals Corporation
    Full Title: A randomized, open-label, single center, phase I, cross-over study to evaluate the pharmacokinetic comparability of deferasirox new tablet formulation with the reference dispersible formulation in ...
    Medical condition: Healthy subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000308-28 Sponsor Protocol Number: ICL670F1102 Start Date*: 2016-03-09
    Sponsor Name:Novartis
    Full Title: A randomized, open label, six sequences, cross-over study in healthy Japanese subjects to evaluate the pharmacokinetic comparability of deferasirox granule formulation with the reference dispersibl...
    Medical condition: Healthy adult subjects
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2019-002221-29 Sponsor Protocol Number: VIT-2763-THAL-201 Start Date*: 2020-02-25
    Sponsor Name:Vifor (International) Inc.
    Full Title: A Phase 2a, Double-blind, Randomised, Placebo-controlled, Parallel Group, Multicentre Study on Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of Multiple Doses of...
    Medical condition: Non-transfusion Dependent Beta-thalassaemia.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10074355 Non-transfusion dependent thalassaemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-004959-23 Sponsor Protocol Number: NPJ005-DM2-0521 Start Date*: 2018-07-05
    Sponsor Name:neopharma Japan Co., Ltd
    Full Title: A 24-week, Phase IIa, Double blind, Randomized, Parallel Group, Placebo controlled, Exploratory Study to Evaluate the Efficacy and Safety of 5 Aminolevulinic Acid Co-administered with Sodium Ferrou...
    Medical condition: Type 2 Diabetes Mellitus in Patients who have not Achieved Adequate Glycemic Control with Maximum Tolerated Dose of Metformin Daily or Sulfonylurea
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002581-12 Sponsor Protocol Number: MCI-196-E14 Start Date*: 2013-03-14
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Multi-centre, Randomised, Controlled, Parallel Group, Open-label Study Evaluating the Efficacy, Safety and Tolerability of Three Doses of Colestilan (MCI-196) Compared to Standard Therapy with a ...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10020711 Hyperphosphataemia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-002582-35 Sponsor Protocol Number: MCI-196-E16 Start Date*: 2013-03-14
    Sponsor Name:Mitsubishi Tanabe Pharma Corporation (MTPC)
    Full Title: A Multi-centre, Open-label Study Evaluating the Safety and Tolerability of Colestilan (MCI-196) in Paediatric Subjects with Chronic Kidney Disease Stages 3b to 5 and with Hyperphosphataemia not on ...
    Medical condition: Hyperphosphataemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10027433 - Metabolism and nutrition disorders 10020711 Hyperphosphataemia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003265-36 Sponsor Protocol Number: AG348-C-022 Start Date*: 2022-05-10
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Subjects With Pyruvate Kinase Deficiency Who Are Regularly T...
    Medical condition: Pyruvate Kinase Deficiency
    Disease: Version SOC Term Classification Code Term Level
    21.1 10010331 - Congenital, familial and genetic disorders 10037682 Pyruvate kinase deficiency anaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) ES (Ongoing) CZ (Ongoing) DK (Ongoing) IT (Prematurely Ended) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002499-15 Sponsor Protocol Number: A536-04 Start Date*: 2012-12-19
    Sponsor Name:ACCELERON PHARMA INC
    Full Title: A Phase 2, Open-Label, Ascending Dose Study to Evaluate the Effects of ACE-536 in Patients with β-Thalassemia Intermedia
    Medical condition: β-thalassemia intermedia
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004850 10062923 Thalassemia intermedia LLT
    15.1 100000004850 10054660 Thalassemia beta LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-000212-34 Sponsor Protocol Number: AG348-C-018 Start Date*: 2021-10-11
    Sponsor Name:Agios Pharmaceuticals, Inc.
    Full Title: A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZ...
    Medical condition: Transfusion-Dependent Alpha- or Beta-Thalassemia
    Disease: Version SOC Term Classification Code Term Level
    22.0 100000004850 10081904 Transfusion dependent thalassemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) DK (Ongoing) IT (Ongoing) BG (Ongoing) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002645-11 Sponsor Protocol Number: SPP1C302 Start Date*: 2013-12-04
    Sponsor Name:SBI Pharmaceuticals Co., Ltd.
    Full Title: An Open-label, Randomized Study to Evaluate Safety, Tolerability and Pharmacokinetics of 5-ALA/SFC in Cancer Patients with Solid Tumors with Chemotherapy Induced Anemia.
    Medical condition: Cancer Patients with Solid Tumors with Chemotherapy Induced Anemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10005329 - Blood and lymphatic system disorders 10002034 Anaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2013-002682-19 Sponsor Protocol Number: PHI113633 Start Date*: 2013-12-20
    Sponsor Name:GlaxoSmithKline, S.A.
    Full Title: A Phase 2B, randomized, blinded, dose-ranging, active-controlled, parallel-group, multi-center study to evaluate the dose response relationship of GSK1278863 over the first 4 weeks of treatment and...
    Medical condition: Anemia associated with chronic kidney disease.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004857 10064848 Chronic kidney disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) SE (Completed) CZ (Completed) GB (Completed) DK (Completed) HU (Completed) FR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 23:01:50 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA